CLDN18 and gastric cancer: Next, we found that a PI3K inhibitor (PI3Ki)—Pictilisib could reverse PI3K/AKT-mTOR-FAS signaling activation (Fig. 5F), and directly inhibit the proliferation of GC cells with CLDN18-ARHGAP fusion (Appendix Fig. S5).